After its endocytosis from the colloid, some thyroglobulin (Tg) is transcytosed intact across thyrocytes, accounting in part for its presence in the circulation. We previously showed that megalin (gp330), an endocytic Tg receptor, mediates apical to basolateral Tg transcytosis. Here we investigated whether a portion of megalin remains combined with Tg after its transcytosis, using studies with cultured thyroid cells and in vivo observations. FRTL-5 cells, a rat thyroid cell line, cultured on filters in dual chambers form tight junctions and exhibit features of polarity, with expression of megalin exclusively on the upper (apical) surface. After the addition of unlabeled Tg to the upper chamber and incubation at 37 C, some Tg was transcytosed intact across FRTL-5 cells into the lower chamber. Two antimegalin ectodomain antibodies precipitated transcytosed Tg in fluids collected from the lower chamber. After the addition of Tg to surface-biotinylated FRTL-5 cells, an anti-Tg antibody and the two antimegalin ectodomain antibodies precipitated high molecular mass biotinylated material in fluids collected from the lower chamber, corresponding to much of the megalin ectodomain, as well as smaller amounts of lower molecular mass material. The results indicate that Tg transcytosed across FRTL-5 cells remains complexed with megalin ectodomain components, which we refer to as megalin secretory components.
lower chamber, corresponding to much of the megalin ectodomain, as well as smaller amounts of lower molecular mass material. The results indicate that Tg transcytosed across FRTL-5 cells remains complexed with megalin ectodomain components, which we refer to as megalin secretory components.
In aminotriazole-treated rats, which develop increased megalinmediated Tg transcytosis, antimegalin antibodies precipitated some of the Tg in the serum. Tg was also precipitated by antimegalin antibodies in sera from patients with Graves' disease, in which we found increased megalin expression on the apical surface of thyrocytes. In contrast, in thyroidectomized patients with metastatic papillary thyroid carcinoma, in whom Tg is directly secreted by neoplastic thyroid cells into the circulation rather than transcytosed, serum Tg was not precipitated by antimegalin antibodies. The detection of Tgmegalin complexes may help identify the source of serum Tg in patients with thyroid diseases. (J Clin Endocrinol Metab 85: 3458 -3467, 2000) T HYROGLOBULIN (Tg), the precursor of thyroid hormones, is synthesized by thyrocytes and secreted into the follicle lumen, where it is stored as the major component of colloid (1) (2) (3) . Hormone release requires retrieval of Tg from the colloid by thyrocytes and proteolytic cleavage along the lysosomal pathway (1) (2) (3) . However, some internalized Tg bypasses the lysosomal pathway and is transcytosed intact across thyrocytes (3) (4) (5) .
Transcytosis of Tg from the colloid is thought to be one pathway by which Tg enters the circulation (3) (4) (5) . However, Tg may escape from the thyroid in other ways, and the relative importance of transcytosis apparently differs in various thyroid states. Transcytosis of Tg is believed to occur to only a limited extent under physiological conditions, as evidenced by the finding that in healthy subjects living in geographical areas with normal iodine intake, serum Tg levels are usually low or undetectable (6, 7) . It is thought, however, that heightened TSH stimulation increases Tg transcytosis (5) . In support of this, we previously provided evidence (8) that increased Tg transcytosis accounts for elevated serum Tg levels in rats with aminotriazole goiter, an experimental model in which increased TSH release from the pituitary leads to massive Tg endocytosis (9) . Elevated Tg levels are also seen in patients with Graves' disease (10) , in whom TSH-like stimulation results from TSH receptor-stimulating autoantibodies (11) . However, in other conditions, different mechanisms are probably responsible for passage of Tg into the bloodstream. In nontoxic goiter and subacute thyroiditis, passage of Tg into the circulation is thought to result mainly from leakage of Tg from the colloid as a consequence of disruption of the follicular epithelium (12, 13) . In papillary thyroid carcinoma, Tg is thought to be directly secreted by neoplastic thyroid cells into the circulation (14, 15) .
We have recently shown that megalin (gp330) mediates transcytosis of Tg by thyroid cells (8) . Megalin is a member of the low density lipoprotein (LDL) receptor family (16, 17) , which includes the LDL receptor, the very low density li-poprotein receptor, and the LDL receptor-related protein.
The structure of megalin is characterized by a large extracellular domain, with four cysteine-rich ligand binding repeats, a single transmembrane domain, and a relatively short cytoplasmic tail (16, 17) , which bears the signal for endocytosis after ligand binding to the ectodomain. Megalin has been shown to mediate endocytosis of multiple, unrelated ligands via coated pits (18 -22) . In immunohistochemical studies, megalin has been found on the apical surface of a restricted group of absorptive epithelial cells (23, 24) . In the thyroid, megalin is expressed exclusively on the apical surface of thyrocytes, directly facing the follicle lumen (23, 24) . Based on the assumption that physiological ligands of megalin are present in fluids to which the receptor is exposed (18 -22) , we postulated that megalin in the thyroid is an endocytic receptor for Tg. In support of this hypothesis, we found that 1) Tg binds to megalin in solid phase assays with features of high affinity receptor-ligand interactions (25) ; 2) megalin expression on thyroid cells is TSH dependent (8, 26) ; and 3) megalin mediates binding and uptake of Tg in cultured thyroid cells (26) . More recently, we found that megalin-mediated endocytosis of Tg by cultured thyroid cells largely results in transcytosis of intact Tg from the apical to the basolateral cell membrane (8) . Evidence that megalin mediates Tg transcytosis was also obtained in vivo in rats treated with aminotriazole (8) .
The present study was undertaken to determine whether a portion of megalin remains complexed with Tg after its transcytosis and release from the basolateral surface of thyroid epithelial cells. We considered this possibility because of findings with the poly Ig receptor, which mediates transcytosis of polymeric IgA across intestinal epithelial cells or hepatocytes from the basolateral to the apical cell surface (27) . Like megalin, the poly Ig receptor is an integral membrane protein. After endocytosis, IgA travels with the receptor to the apical membrane where the receptor is cleaved by proteolysis, releasing the ligand complexed with a soluble portion of the receptor (the secretory component), which lacks the cytoplasmic domain. In the present study we provide evidence that Tg transcytosed by thyroid cells is complexed with a large extracellular portion of megalin. This information may be of diagnostic value in certain patients with thyroid diseases by permitting identification of the source of circulating Tg.
Materials and Methods

Tg preparations
Tg was purified from frozen rat thyroids by ammonium sulfate precipitation and column fractionation, as previously described (8, 25, 26, 28) . Tg preparations were analyzed by both nonreducing and reducing SDS-PAGE, followed by Coomassie staining or Western blotting, as previously reported (8, 25, 26, 28) . Under nonreducing conditions two bands were seen at about 660 and 330 kDa. The 660-kDa band corresponded to covalently linked Tg dimers. Size exclusion gel chromatography showed that almost all (ϳ95%) of the 330-kDa band represented monomers derived from noncovalently associated Tg dimers that had been dissociated by SDS-PAGE, with a small fraction (ϳ5%) of free Tg monomers. Under reducing conditions, two bands, one slower and one faster, were seen, as previously described (14, 29) . Other Tg products with lower molecular masses were present in minimal amounts.
Antibodies
A rabbit antihuman Tg antibody cross-reactive with Tg from other species was purchased from Axle (Westbury, NY). A horseradish peroxidase (HRP)-conjugated mouse monoclonal anti-human Tg antibody cross-reactive with Tg from other species was obtained from DAKO Corp. (Carpinteria, CA).
A rabbit antibody, designated A55, prepared against immunoaffinitypurified rat megalin and a mouse monoclonal antibody, designated 1H2, that reacts with rat megalin ectodomain epitopes in the second cluster of ligand binding repeats were previously described (30) . Both of these antibodies cross-react with human megalin (our unpublished observation). A rabbit antibody prepared against a megalin-glutathione-S-transferase (GST) fusion protein, which includes the second cluster of ligand binding repeats, was previously described (23, 30) . A rabbit antibody, prepared against a peptide corresponding to a sequence in the cytoplasmic tail of rat megalin, designated Rb3, was previously described (23) . None of the antimegalin antibodies reacted with the Tg preparation used in this study (not shown).
Cell cultures
Fisher rat thyroid cells (FRTL-5; American Type Culture Collection, Manassas, VA) were cultured as previously described (31, 32) in Coon's F-12 medium containing 5% FCS and a mixture of six hormones. We previously showed that the FRTL-5 cells cultured under these conditions synthesize and secrete intact Tg after radiometabolic labeling (8) , which indicates that they maintain functions of differentiated thyroid cells.
Transcytosis experiments
As previously described (8), FRTL-5 cells were cultured on high density large pore (3-m) filters in cell culture inserts (Becton Dickinson and Co., Bedford, MA) placed in 24-well plates. These devices allow polarization of the cells and make it possible to trace transport of molecules across the cell layer, from the upper (insert) to the lower (cell culture well) chamber. Cells were used at complete confluence. The mean number of cells at confluence was 5.2 ϫ 10 4 cells/well, and the mean amount of protein in cell lysates was 5.03 g/well. In certain transcytosis experiments, before plating on filters, FRTL-5 cells were surface labeled with biotin, using EZ-Link Sulfo-NHS-LC-biotin from Pierce Chemical Co. (Rockford, IL), according to the manufacturer's instructions.
In transcytosis experiments FRTL-5 cells were incubated at 37 C with unlabeled Tg (50 g/mL in Coon's F-12 medium, 5 mmol/L CaCl 2 , 0.5 mmol/L MgCl 2 , and 0.5% ovalbumin). Tg was added in a volume of 200 L to the upper chamber, and the lower chamber was rinsed with 200 L buffer without Tg. After 6 h, the medium from the lower chamber was collected and subjected to immunoprecipitation, as described below.
Experimental animals
Serum samples were obtained in a previous study (8) from 12 female Lewis rats, weighing 100 -120 g (Charles River Laboratories, Inc., Wilmington, MA). Six rats received aminotriazole (3-amino-1,2,4-triazole, Sigma, St. Louis, MO) in drinking water (0.04%) for 12 days, and six rats that had not received aminotriazole were used as controls. Animal care and sacrifice procedures were in accordance with institutional guidelines. Serum samples were obtained from each rat at death and stored at Ϫ20 C until used for immunoprecipitation experiments described below.
Patients
Serum samples from 15 patients with thyroid diseases were collected at the Department of Endocrinology, University of Pisa (Pisa, Italy). Seven patients had Graves' disease (1 man and 6 women; mean age, 40.2 Ϯ 18.4 yr; age range, 26 -69 yr); 3 of them were untreated hyperthyroid, and 4 were euthyroid under methimazole therapy. Eight patients had metastatic papillary thyroid carcinoma (1 man and 7 women; mean age, 57.6 Ϯ 13.2 yr; age range, 29 -72 yr). They had all been treated with total thyroidectomy and ablation of residual thyroid tissue with radioiodine therapy and were hypothyroid due to l-T 4 therapy with-drawal for whole body scan. In addition, we used serum samples from 5 normal subjects with no evidence of thyroid disease.
All serum samples were tested for the presence of anti-Tg autoantibodies, using a commercial kit (anti-Tg MELISA, Byk Gulden SpA, Milan, Italy) and for the presence of antimegalin autoantibodies, as previously described (33) . None of the sera used here had anti-Tg or antimegalin autoantibodies.
The diagnosis of Graves' disease was based on the presence of hyperthyroidism associated with diffuse goiter and circulating anti-TSH receptor autoantibodies. The diagnosis of papillary thyroid carcinoma was based on histological findings.
Immunohistochemistry
Archival formalin-fixed, paraffin-embedded thyroid specimens from three patients with Graves' disease and from three patients with papillary thyroid carcinoma were obtained from the Department of Pathology of the University of Athens (Athens, Greece). The diagnosis of Graves' disease and papillary thyroid carcinoma was based on clinical, histological, and laboratory findings. Surgery was performed in all cases for therapeutic purposes. At the time of surgery, the three patients with Graves' disease were euthyroid under carbimazole treatment, and the three patients with papillary thyroid carcinoma were untreated. Normal thyroid tissue was obtained from the contralateral lobe of two thyroid glands of patients subjected to total thyroid thyroidectomy for papillary thyroid carcinoma. These two patients were untreated at the time of surgery. As a positive control for megalin staining, we used an archival formalin-fixed, paraffin-embedded kidney specimen obtained from the Department of Pathology of the Massachusetts General Hospital (Boston, MA), which was collected at autopsy from a patient without kidney disease.
Immunohistochemistry was performed with 5-m sections from paraffin-embedded specimens, using a previously described procedure (34 -36) . Briefly, sections were deparaffinized, dehydrated, microwaved, and treated with methanol. Sections were then incubated with the monoclonal antimegalin antibody 1H2 (20 g/mL), followed by biotin-labeled horse antimouse IgG (Vector Laboratories, Inc., Burlingame, CA) and HRP-conjugated streptavidin (Biogenix, San Ramon, CA). The chromogen 3-amino-9-ethylcarbazole (Aldrich Chemical Co., Inc., Milwaukee, WI) was used as a substrate for HRP. Sections were counterstained with Gill's hematoxylin (Fisher Scientific, Fairlawn, NJ).
Immunoprecipitation experiments
Samples were incubated overnight at 4 C with 50 L protein A agarose beads (Pharmacia Biotech, Piscataway, NJ) coupled at saturation with the rabbit anti-Tg antibody, with A55, with the antimegalin-GST antibody, with Rb3, or, as a control, with normal rabbit IgG. Beads were washed extensively and resuspended in nonreducing Laemmli buffer. Samples were boiled and spun down, and supernatants were subjected to SDS-PAGE and Western blotting, as described below.
Western blotting
Samples were subjected to nonreducing 5-16% SDS-PAGE and blotted onto nitrocellulose membranes. To detect Tg, membranes were incubated with the HRP-conjugated mouse anti-Tg antibody (1:400). To detect biotinylated proteins, membranes were incubated with HRPconjugated streptavidin (Bio-Rad Laboratories, Inc., Hercules, CA; 1:1000). Bands were detected using a chemiluminescent substrate kit (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD). The pixel density of the bands obtained was measured in scanned images using personal computer software (NIH Imager 2.1).
Tg assay in human sera
Tg was measured in human sera by RIA, using a kit from Diagnostic Products (Los Angeles, CA). Before Tg measurement, serum samples were incubated overnight at 4 C with protein A beads coupled at saturation with A55 or, as a control, with normal rabbit IgG. Beads were spun down, and Tg was measured in the supernatants.
Statistical analysis
Unpaired t test was performed using personal computer software (StatView, Abacus Concepts, Berkeley, CA).
Results
Tg transcytosed by FRTL-5 cells is precipitated by antimegalin antibodies
FRTL-5 cells were cultured on permeable filters in the upper chamber of dual chambered devices. We previously showed (8) that under these culture conditions FRTL-5 cells exhibit features of polarity, notably megalin expression exclusively at the upper surface of the cell layer and the presence of microvilli and coated pits on the upper surface, as seen by electron microscopy. We also showed (8) that with cells cultured under these conditions there is no paracellular leakage of Tg from the upper to the lower chamber.
We performed transcytosis assays by adding preparations of unlabeled rat Tg (comprising both the 660-and 330-kDa forms) to the upper chamber of dual chambered devices containing FRTL-5 cells, followed by incubation at 37 C. After 6 h, fluids were collected from the lower chamber, which, as in our previous study (8) , were found by Western blotting to contain exclusively 330-kDa Tg (not shown).
To investigate whether transcytosed Tg is complexed with megalin, we performed immunoprecipitation experiments in fluids collected from the lower chamber, using three previously described antimegalin antibodies (23, 30) . To detect megalin ectodomain epitopes, we used two rabbit antibodies: 1) A55, an antibody reactive with multiple ectodomain epitopes; and 2) antimegalin-GST, an antibody against a megalin-GST fusion protein, which includes a sequence corresponding to the second cluster of ligand binding repeats. To detect the megalin cytoplasmic tail, we used Rb3, a rabbit antibody against a synthetic peptide corresponding to a sequence in the cytoplasmic tail of rat megalin. Normal rabbit IgG was used as a control.
Fluids collected from the lower chamber were incubated with protein A beads coupled with a rabbit polyclonal anti-Tg antibody or with each of the three antimegalin antibodies. After immunoprecipitation, samples were subjected to nonreducing SDS-PAGE, followed by Western blot analysis with a monoclonal anti-Tg antibody. Normal rabbit IgG did not precipitate transcytosed Tg (not shown). The rabbit anti-Tg antibody precipitated intact 330-kDa Tg (Fig. 1, lane  1) . Furthermore, both antimegalin ectodomain antibody, A55 (Fig. 1, lane 2) , and the antimegalin-GST fusion protein (Fig.  1, lane 3 ) precipitated 330-kDa Tg, whereas the antimegalin cytoplasmic tail antibody Rb3 did not (Fig. 1, lane 4) . The results indicate that Tg transcytosed by FRTL-5 cells is complexed with a portion of megalin devoid of the cytoplasmic tail.
To obtain information concerning the proportion of transcytosed Tg complexed with megalin, we measured the pixel density of the bands obtained by Western blotting shown in Fig. 1 . The pixel density of the band precipitated by the anti-Tg antibody was 38.34 pixels/cm 2 ( Fig. 1, lane 1) . The pixel densities of the bands precipitated by A55 and the anti-megalin-GST fusion protein antibody were, respectively, 24 .55 pixels/cm 2 ( Fig. 1, lane 2) and 26.58 pixels/cm (Fig. 1, lane 3) . We estimated that 65-70% of the transcytosed Tg was precipitated by the two antimegalin antibodies, representing the proportion complexed with megalin.
Megalin secretory components complexed with Tg transcytosed by FRTL-5 cells
We made several attempts to characterize further the megalin secretory component in Tg transcytosis experiments with FRTL-5 cells. After immunoprecipitation of fluids collected from the lower chamber with the antimegalin ectodomain antibody A55, we performed Western blot analysis with 1H2, a mouse monoclonal antibody that reacts with the second cluster of megalin ligand binding repeats, in the extracellular portion of the molecule (30) . A faint band of high molecular mass was found, but only in some experiments (not shown). Because of the low sensitivity of this method for the detection of megalin secretory components, we tried another approach, namely biotin labeling of surface proteins on FRTL-5 cells. After labeling, cells were plated on permeable filters in the dual chambered devices; 24 h later, unlabeled Tg was added to the upper chamber, and the cells were incubated for 6 h at 37 C. The fluid from the lower chamber was subjected to immunoprecipitation with the rabbit anti-Tg antibody or with the three rabbit antimegalin antibodies (A55, anti-megalin-GST fusion protein, or Rb3), followed by Western blotting and detection of biotinylated proteins with streptavidin. As shown in Fig. 2 , both the anti-Tg (lane 2) and the two antimegalin ectodomain antibodies (A55 and antimegalin-GST fusion protein; lanes 3 and 4) precipitated an intense band of very high molecular mass (Ͼ500 kDa). In addition, other bands of lower molecular mass and lesser intensity were precipitated by anti-Tg, A55, or antimegalin-GST antibodies (Fig. 2, lanes 2-4) . Among these bands, two with molecular masses of more than 200 kDa (ϳ300 and ϳ350 kDa), were particularly intense. Rb3, the rabbit antibody against the megalin cytoplasmic tail, did not precipitate any band (Fig. 2, lane 5) , indicating that megalin transcytosed with Tg across FRTL-5 cells had lost its cytoplasmic domain. No band was precipitated by normal rabbit IgG, which was used as a control (not shown).
Based on these results, we conclude that the major secretory component of megalin corresponds to most of the ectodomain of the receptor, and that smaller megalin products are probably derived from partial cleavage of the molecule during its passage across the cells or at the basolateral surface. These smaller products remain complexed with transcytosed Tg, as shown by immunoprecipitation with the anti-Tg antibody (Fig. 2, lane 2) .
To obtain information concerning the relative amounts of the megalin band with the highest molecular mass precipitated by the anti-Tg antibody or by antimegalin antibodies, we measured the pixel densities of the bands obtained in immunoprecipitation experiments. The pixel density of the band precipitated by the anti-Tg antibody was 42.65 pixels/ cm 2 ; the pixel densities of the bands precipitated by A55 and the antimegalin-GST fusion protein antibody were, respec- tively, 54.98 and 46.13 pixels/cm 2 . The results suggest that 75-90% of the major megalin secretory component was complexed with transcytosed Tg.
To investigate whether release of megalin into the lower chamber occurs in the absence of Tg transcytosis, we performed experiments with biotinylated FRTL-5 cells in which buffer lacking Tg was added to the upper chamber. The material in the lower chamber was subjected to immunoprecipitation with A55, followed by Western blotting with streptavidin. As shown in Fig. 2 (lane 1) , only extremely faint bands were precipitated by A55. The results indicate that transcytosis of megalin occurs only to a minimal extent in the absence of added Tg. The small amount of megalin released into the lower chamber in the absence of exogenously added Tg may have been complexed with endogenous Tg, which is known to be synthesized and secreted by FRTL-5 cells (31, 32), as we have found in the cells used here (8) . The results suggest that release of the megalin secretory component does not occur constitutively in the absence of ligand binding.
Detection of circulating Tg-megalin complexes in vivo
Model of aminotriazole goiter in rats. To investigate megalinmediated transcytosis of Tg in vivo, we previously used the model of aminotriazole goiter in rats (8) . Aminotriazole inhibits iodination of newly synthesized Tg, resulting in increased TSH release from the pituitary (9). After several days, progressive changes occur in the thyroid due to the stimulatory effects of TSH, characterized by enlargement and proliferation of thyroid cells with massive endocytosis of Tg from the colloid (9). By 10 -12 days the colloid is almost completely depleted (9) . We found that the rats treated with aminotriazole had a striking increase in megalin expression on thyrocytes as well as elevated Tg levels and reduced T 3 levels in the serum, supporting the conclusion that Tg internalized by megalin is transcytosed (8) .
To investigate whether circulating Tg in aminotriazoletreated rats was complexed with megalin, we used serum samples obtained in our previous study (8) from six rats treated with aminotriazole for 12 days. Serum Tg levels in these rats were markedly and significantly (P ϭ 0.0021) higher than those in normal untreated rats (aminotriazoletreated rats, 1037 Ϯ 42 U/mL; normal untreated rats, 272 Ϯ 225 U/mL) (8) . Serum samples were subjected to immunoprecipitation with the rabbit anti-Tg antibody or with the antimegalin ectodomain antibody A55, followed by Western blotting with the mouse anti-Tg antibody. As shown in Fig.  3A , 330-kDa Tg was precipitated by both the anti-Tg antibody (lane 1) and A55 (lane 2) in sera from aminotriazoletreated rats, whereas in normal rats Tg was precipitated by the anti-Tg antibody (Fig. 3B, lane 1) , but not by A55 (Fig. 3B,  lane 2) . No bands were precipitated by normal rabbit IgG, which was used as a control (not shown). The pixel density of the band precipitated by the anti-Tg antibody in aminotriazole-treated rats was 930 pixels/cm 2 , and the pixel density of the band precipitated by A55 was 37.5 pixels/cm 2 . The results indicate that about 4% of circulating Tg in aminotriazole rats was complexed with megalin.
The same amount of serum (1000 L) was used for immunoprecipitation experiments in untreated rats and in rats treated with aminotriazole. However, because in untreated rats serum Tg levels were significantly lower than those in rats treated with aminotriazole, and in view of the relatively low percentage of serum Tg precipitated by A55 in rats treated with aminotriazole, it is possible that Tg was also complexed with megalin in untreated rats, but was not precipitated by A55 in amounts sufficient to be detected by Western blotting.
Patients with Graves' disease. In humans, elevated serum Tg levels are seen in association with intense TSH or TSH-like stimulation, as occurs in Graves' disease due to TSH receptor-stimulating autoantibodies (11) . In this condition there is increased Tg endocytosis with varying degrees of colloid depletion (37) . Although in Graves' disease there are elevated thyroid hormone levels in the serum, indicating lysosomal degradation of Tg, high levels of serum Tg are also seen, which are thought to result from transcytosis (14, 15) . In contrast, in papillary thyroid carcinoma, in which increased serum levels of Tg are seen, mechanisms other than transcytosis are thought to be responsible, because the neoplastic thyroid cells are not organized in follicles and are therefore not exposed to colloid. The cells, however, are sufficiently differentiated to synthesize Tg, which is apparently directly secreted into the circulation (14, 15) .
To investigate megalin-mediated transcytosis of Tg in humans, we studied patients with Graves' disease and papillary thyroid carcinoma. We first assessed megalin expression in the thyroid by immunohistochemistry, using archival formalin-fixed specimens. To detect megalin, we used the mouse monoclonal antibody 1H2, which cross-reacts with human megalin. As positive controls, we used sections of normal human kidney prepared from formalin-fixed specimens, which, as expected, showed staining restricted to the brush border region of proximal tubules (not shown). However, the staining was of only moderate intensity, indicating that the sensitivity of megalin detection was low under the conditions used here, which explains why megalin was not detected on normal thyroid cells in two specimens studied (Fig. 4A ) even though megalin expression has been demonstrated in normal thyrocytes in other studies (23, 24) . In thyroid sections of three patients with Graves' disease, apical staining for megalin was found on many thyrocytes and was especially intense in follicles depleted of colloid (Fig. 4B) . This finding is consistent with the conclusion that TSH-like stimulation up-regulates megalin expression on human thyrocytes, as previously shown in rat thyrocytes (8) . In sections from three patients with papillary thyroid carcinoma, moderate diffuse intracellular staining of thyroid cells was found, with no distinct surface staining (Fig. 4C) . This pattern suggests that megalin is not normally transported to the surface of the neoplastic cells, perhaps as the result of defective chaperoning or assembly.
We then performed immunoprecipitation experiments to determine whether any serum Tg is complexed with megalin in patients with Graves' disease and metastatic papillary thyroid carcinoma. The patients with metastatic papillary carcinoma had been subjected to total thyroidectomy and ablation of residual thyroid tissue with radioiodine therapy. Furthermore, after administration of a tracer dose (5 mCi) of 131 I, whole body scan revealed only thyroid carcinoma metastases. In addition, no tissue in the neck or mediastinum was revealed by whole body scan after administration of a therapeutic dose (100 -120 mCi) of 131 I. Thus, in these patients the only source of serum Tg was metastases of thyroid carcinoma. None of the serum samples used in this study had anti-Tg or anti-megalin autoantibodies.
Serum samples were incubated with protein A beads coupled with the rabbit anti-Tg antibody or with the antimegalin ectodomain antibody A55, which cross-reacts with human megalin, followed by Western blot analysis with the mouse anti-Tg antibody. As shown in Fig. 5A , in sera from patients with Graves' disease 330-kDa Tg was precipitated by the anti-Tg antibody (lane 1) and by A55 (lane 2). In contrast, in serum samples from patients with metastatic papillary thyroid carcinoma, Tg was precipitated by the anti-Tg antibody (Fig. 5B, lane 1) , but not by A55 (Fig. 5B, lane 2) . No bands were precipitated by normal rabbit IgG, which was used as a control (not shown). We also performed immunoprecipitation experiments in serum samples from five normal subjects. However, Tg levels in these samples were undetectable by RIA, and serum Tg was not precipitated by either the anti-Tg antibody or A55 (not shown).
The pixel density of the band precipitated by the anti-Tg antibody in Graves' sera was 39.1 pixels/cm 2 , and the pixel density of the band precipitated by the antimegalin ectodomain antibody (A55) was 9.96 pixels/cm 2 . The results indicate that about 25% of circulating Tg in patients with Graves' disease was complexed with megalin.
We then evaluated the effect of preadsorption of serum samples with antimegalin antibodies on serum Tg levels in patients with Graves' disease and in patients with metastatic papillary thyroid carcinoma. Serum samples were incubated with protein A beads coupled with A55 or, as a control, with normal rabbit IgG, followed by Tg measurement by RIA. After preadsorption with normal rabbit IgG beads, the mean serum Tg level in patients with Graves' disease was 90.7 Ϯ 61.4 ng/mL (range, 25-215 ng/mL). Preadsorption with A55 beads resulted in a reduction of serum Tg levels to 46.4 Ϯ 32.2 ng/mL (range, 5-100 ng/mL), indicating that about 50% of detectable Tg in the serum of patients with Graves' disease was complexed with megalin. After preadsorption with normal rabbit IgG beads, the mean serum Tg level in patients with metastatic papillary thyroid carcinoma was 454 Ϯ 485 ng/mL (range, 25-215 ng/mL). The mean serum Tg level after preadsorption with A55 was 468 Ϯ 462 ng/mL (range, 90 -1505 ng/mL), indicating that virtually all of the detectable Tg in the serum from patients with metastatic papillary thyroid carcinoma was recovered after adsorption with A55. As shown in Fig. 6 , the mean proportion of serum Tg levels recovered after preadsorption with A55 beads was significantly lower (P ϭ 0.006) in patients with Graves' disease (51.1 Ϯ 32.1%) than in patients with metastatic papillary thyroid carcinoma (103.2 Ϯ 32.8%).
Discussion
In the present study we provide evidence that after megalin-mediated endocytosis of Tg from the colloid, Tg remains complexed with a large portion of megalin ectodomain during its transit across the cell (transcytosis) and after its release into the circulation. We refer to the portions of megalin complexed with Tg as its secretory components, in keeping with the terminology used for the portion of the poly Ig receptor released in soluble form with its ligand (27) .
As noted previously, megalin is a member of the LDL receptor family (16, 17) that is expressed on the apical surface of thyrocytes (22, 23) . In previous studies we have shown that megalin is a high affinity receptor for Tg (25) , capable of mediating Tg uptake by cultured thyroid cells (26) . More recently, we demonstrated that after megalin-mediated endocytosis, Tg is transcytosed intact from the apical to the basolateral surface of thyroid epithelial cells (8) . Our findings support and extend studies by Herzog and associates (4, 5) , who demonstrated Tg transcytosis across pig thyroid cells
FIG. 6. Preadsorption of serum with antimegalin antibodies reduces
Tg levels in patients with Graves' disease (GD), but not in thyroidectomized patients with metastatic papillary thyroid carcinoma (MTC). Serum samples from seven patients with Graves' disease and from eight patients with metastatic papillary thyroid carcinoma were incubated with protein A beads coupled with the antimegalin ectodomain antibody A55 or with normal rabbit IgG. Beads were spun down, and Tg was measured in the supernatant by RIA. Values are expressed as the percentage of Tg recovered Ϯ SD after preadsorption with A55, calculated according to the following formula: % of Tg recovered ϭ (Tg after preadsorption with A55/Tg after preadsorption with normal rabbit IgG) ϫ 100. P ϭ 0.006, by t test. and postulated that Tg transcytosis is a major mechanism for its passage into the bloodstream (8) .
In our previous (8) and present study we used FRTL-5 cells cultured on permeable filters in the upper chamber of dual chambered devices. We found that when Tg was added to the upper chamber, it was transported intact into the lower chamber by transcytosis (8) . We concluded that passage of Tg across FRTL-5 cells was from the apical to the basolateral surface, because under the conditions used, FRTL-5 cells express megalin (an apical membrane receptor) exclusively at the upper surface, where microvilli and clathrin-coated pits are seen by electron microscopy (8) .
Evidence that passage of Tg occurred by transcytosis and not by paracellular leakage was provided by several findings, notably the inhibitory effects of low temperature and of the microtubule-disruptive agent colchicine, the inhibitory effects of specific megalin competitors, and the low passage across the cell layer of [ 3 H]mannitol, a molecule of very low mass (8) . Furthermore, FRTL-5 cells cultured under the conditions used here form tight junctions, as indicated by the presence of junctional complexes by electron microscopy and by the expression of occludin, a tight junction-associated protein (8, 38) .
In the present study we show that Tg transcytosed by FRTL-5 cells is complexed with megalin secretory components. Thus, two polyclonal antimegalin ectodomain antibodies, one against multiple ectodomain epitopes (A55) and one prepared against the second cluster of ligand binding repeats (anti-megalin-GST), precipitated 330-kDa Tg transcytosed by FRTL-5 cells. In contrast, a rabbit antibody against a peptide sequence in the megalin cytoplasmic domain (Rb3) failed to precipitate transcytosed Tg, indicating that megalin released as a complex with Tg is devoid of the cytoplasmic tail. Further evidence in support of this conclusion was provided by experiments in which Tg transcytosis across surface biotinylated FRTL-5 cells resulted in the release of biotinylated material into the lower chamber that was precipitated by the two antimegalin ectodomain antibodies, but not by the antibody against the megalin cytoplasmic domain. The main megalin secretory component was a band of very high molecular mass (Ͼ500 kDa), which must represent a large portion of the megalin ectodomain. However, several other lower molecular mass bands were also precipitated (although in lower amounts). All megalin components were precipitated by a rabbit anti-Tg antibody, indicating that they were complexed with transcytosed Tg.
Herzog and associates (4, 5) have provided evidence that transcytosis of Tg across pig thyroid cells occurs in microvesicles. Based on their findings (4, 5) and on our observations we postulate the following events in Tg transcytosis. Megalin mediates Tg endocytosis at the apical surface of thyrocytes via clathrin-coated pits (where megalin is concentrated). Somewhere in the endosomal compartment vesicles containing Tg-megalin complexes are formed, which travel to basolateral surfaces, thereby bypassing the lysosomal pathway. At some stage during passage across the cells, megalin is cleaved, probably close to the transmembrane domain, leaving a large portion of the ectodomain complexed in soluble form with Tg. Additional cleavage could account for the smaller megalin fragments that are transcytosed. At basolateral surfaces, the vesicles fuse with the cell membrane, releasing their soluble content into the extracellular compartment. Clearly, future studies aimed at tracing the intracellular route of Tg and megalin using confocal and electron microscopy and cell fractionation techniques will be required to provide direct documentation of this process. Furthermore, the biochemical mechanisms responsible for targeting of Tg-megalin complexes toward the transcytosis pathway and for cleavage of megalin are unknown and require further investigations. These investigations will be aimed also at identifying the main cleavage site of megalin in the ectodomain, which should permit determination of the size of the megalin secretory component that is released complexed with Tg. Based on the results obtained in our previous studies with intact megalin (25, 26) , it is likely that Tg binds to the megalin secretory component with high affinity and in a saturable manner. However, we do not have direct evidence for this, and further studies are needed to investigate this issue.
To investigate Tg transcytosis in vivo, we studied an experimental model in rats as well as in patients with thyroid diseases. We previously presented evidence (8) that rats treated with aminotriazole have increased megalin-mediated transcytosis of Tg associated with markedly increased serum levels of intact 330-kDa Tg. Here we found that some of the serum Tg in aminotriazole-treated rats is complexed with megalin, as shown by immunoprecipitation experiments with the rabbit antimegalin ectodomain antibody A55. Similar results were obtained with sera from patients with Graves' disease, where A55 precipitated intact Tg. Furthermore, by immunohistochemistry we found increased megalin expression on the apical surface of thyrocytes in Graves' patients, especially in small follicles with little colloid, indicative of intense endocytosis. The results support the idea that there is increased Tg transcytosis in Graves' disease (14, 15) and provide new evidence that the process is mediated by megalin. In contrast, in thyroidectomized patients with metastatic papillary thyroid carcinoma serum Tg was not precipitated by A55, even though serum Tg levels in these patients were 4.5-fold higher than those in patients with Graves' disease. This finding as well as the lack of follicles containing colloid and the absence of cell surface staining for megalin support the conclusion that Tg is not transcytosed across neoplastic thyroid cells, but is directly secreted by the cells into the circulation, as previously suggested (14, 15) .
Our present and previous (8) observations provide compelling evidence that megalin can mediate Tg transcytosis both in cultured thyroid cells and in vivo. Furthermore, our findings indicate that megalin-mediated transcytosis is the major mechanism for Tg passage across cultured thyroid cells. Thus, we previously showed that megalin accounts for 65-80% of Tg transcytosis across FRTL-5 cells (8) , and here we found that roughly 65-70% of Tg transcytosed by FRTL-5 cells was complexed with megalin. However, our estimates of the proportion of circulating Tg complexed with megalin were substantially lower in patients with Graves' disease (25-50%) and were drastically lower in aminotriazole-treated rats (ϳ4%). The results suggest that additional transport mechanisms may contribute to the passage of Tg into the circulation in these conditions. However, other explanations are worth considering. Thus, Tg-megalin complexes may dissociate more extensively in vivo than in the cell culture chamber from which transcytosed Tg is recovered in experiments with FRTL-5 cells. Furthermore, Tg-megalin complexes may be cleared more quickly from the circulation than unbound Tg. Further studies are needed to determine the fate of Tg-megalin complexes in vivo and to investigate the possibility that mechanisms other than megalin-mediated transcytosis contribute to Tg transport into the bloodstream. Nevertheless, the finding that in these conditions some serum Tg is complexed with megalin provides compelling evidence that megalin mediates its transcytosis at least in part.
Recently, Druetta et al. (15) developed a method to identify the origin of serum Tg based on the measurement of its hormone content. Because Tg is iodinated exclusively at the apical surface of thyroid cells within the follicle lumen (1), the finding of a high thyroid hormone content is considered to provide evidence that Tg has been derived from the colloid, rather than secreted directly from thyrocytes into the bloodstream (15) . In their study Druetta et al. (15) found no difference in the hormone content of serum Tg between patients with Graves' disease and patients with metastatic papillary thyroid carcinoma (15) . However, although the method used by Druetta et al. (15) appears to be sensitive and accurate, the finding of serum Tg with low hormone content does not exclude the possibility that Tg is derived from the colloid, because some poorly iodinated forms of Tg are present there (1) (2) (3) . We propose that measurement of the proportion of serum Tg complexed with megalin may help determine whether Tg entered the circulation from the colloid. This approach may be used in patients suspected of having papillary thyroid carcinoma before they are subjected to thyroid surgery. Serum Tg in such patients can result either from direct secretion of Tg by tumor cells or from transcytosis of Tg in normal thyroid tissue. The absence of serum Tg bound to megalin would suggest Tg secretion into the blood by tumor cells. Clearly, further studies are needed to standardize the method for measuring the proportion of serum Tg bound to megalin and to evaluate its usefulness in a large series of thyroid patients.
The importance of megalin-mediated transcytosis of Tg under physiological and pathological conditions probably depends in large part on the selectivity of the process and the regulation of megalin expression on thyrocytes. In this regard, we have obtained preliminary data suggesting that immature forms of Tg with a low hormone content are preferentially transcytosed by megalin, even though Tg forms with a higher hormone content are transcytosed to some extent (Marinò , M., et al., manuscript in preparation). Thus, under physiological conditions, where megalin expression on thyrocytes is low, only very small amounts of mature Tg would be lost from the colloid as the result of megalinmediated transcytosis. However, under conditions of massive TSH or TSH-like stimulation, when megalin expression is increased, as shown previously (8, 26) and here in patients with Graves' disease, mature as well as immature forms of Tg may be transcytosed, which may serve to reduce the extent of hormone release by diverting Tg from the lysosomal pathway. Further studies are needed to investigate these hypotheses.
